News

The general secretary of the European Society of Retina Specialists (EURETINA) says the future of AI is here

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

Peter J. McDonnell, MD, and Laura M. Periman, MD, discuss recent innovations in ophthalmology, emphasizing ocular surface disease and the growing complexity of care at EyeCon 2024, held September 27 and 28, in Fort Lauderdale, Florida.

Neltependocel has received both regulatory and reimbursement approval in Japan

Wendy Lee, MD, sat down with Ophthalmology Times to discuss a symposium she participated in at Eyecon 2024 focusing on Thyroid Eye Disease.

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

The NIH-supported findings could pave the way for genetic testing, clinical trials, and therapy development for these diseases.

Dvey-Aharon is an internationally known AI expert and the inventor of AEYE-DS.

Alexandra Miere, MD, PhD, says oculomics is the next big thing in eye care.

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

Carl Awh, MD, FASRS, spoke the value of the international community of retina clinicians connecting at global meetings

Investigadores brasileños preocupados por la aparición de metástasis oculares realizaron un estudio retrospectivo y descubrieron que la frecuencia de metástasis oculares era relativamente baja, según su primer autor Matheus Senna Pereira Ogata, MD.

Evaluando los beneficios de un paquete de expansión, sus costos y riesgos asociados

Sumit Sharma, MD, sat down with Sydney Crago of Modern Retina to discuss his presentation on the 3 tyrosine kinase inhibitors currently in development for the treatment of retina conditions at the Retina Society meeting being held this year in Lisbon, Portugal.

Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina clinicians connecting at meetings around the globe.

This research builds on previous experience that stimulating nicotinic receptors can inhibit experimental myopia

Clare Bailey, MD, shared data from the multi-country study on faricimab for patients with DME and nAMD

Inflammasome Therapeutics has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug, K9.

How retinal imaging can provide clinicians a deeper understanding of myopia

Additionally, FDA grants Fast Track Designation to brepocitinib for non-infectious uveitis.

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of EMA's initial opinion.

New research and EURETINA highlights from the director of the "underdog" eye clinic

The agency confirmed its June 2024 negative opinion after Apellis requested re-examination of the EMA's initial response

Vyznova is for the treatment of bullous keratopathy of the cornea, a sight-threatening and debilitating condition affecting the endothelial cells of the cornea.

TEPEZZA is the first and only medicine approved in Japan to treat active TED.